Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 2
2014 4
2015 2
2016 3
2017 5
2018 4
2019 6
2020 5
2021 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Loscocco GG, et al. Among authors: paoli c. Am J Hematol. 2024 Jan;99(1):68-78. doi: 10.1002/ajh.27136. Epub 2023 Oct 17. Am J Hematol. 2024. PMID: 37846894
Facing erythrocytosis: Results of an international physician survey.
Rumi E, McMullin MF, Harrison C, Ellis MH, Barzilai M, Sarid N, Mesa R, Paoli C, Angona A, Sant'Antonio E, Ferretti VV, Cavalloni C, Casetti IC, Trotti C, Barbui T. Rumi E, et al. Among authors: paoli c. Am J Hematol. 2019 Sep;94(9):E225-E227. doi: 10.1002/ajh.25545. Epub 2019 Jun 10. Am J Hematol. 2019. PMID: 31148218 Free PMC article. No abstract available.
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T. Guglielmelli P, et al. Among authors: paoli c. Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. Blood Adv. 2022. PMID: 34753179 Free PMC article. No abstract available.
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature.
Coltro G, Mannelli F, Vergoni F, Santi R, Massi D, Siliani LM, Marzullo A, Bonifacio S, Pelo E, Pacilli A, Paoli C, Franci A, Calabresi L, Bosi A, Vannucchi AM, Guglielmelli P. Coltro G, et al. Among authors: paoli c. Clin Exp Med. 2020 May;20(2):313-320. doi: 10.1007/s10238-020-00616-5. Epub 2020 Feb 17. Clin Exp Med. 2020. PMID: 32065308 Review.
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.
Guglielmelli P, Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, Maccari C, Paoli C, Romagnoli S, Bartalucci N, Vannucchi AM. Guglielmelli P, et al. Among authors: paoli c. Blood Adv. 2022 May 10;6(9):2927-2931. doi: 10.1182/bloodadvances.2021006350. Blood Adv. 2022. PMID: 35020812 Free PMC article. No abstract available.
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: paoli c. Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31. Am J Hematol. 2022. PMID: 35338671 Free PMC article.
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Barbui T, et al. Among authors: paoli c. Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. Blood Cancer J. 2022. PMID: 36385103 Free PMC article. No abstract available.
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P. Pacilli A, et al. Among authors: paoli c. Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x. Blood Cancer J. 2018. PMID: 30467377 Free PMC article.
36 results